<?xml version='1.0' encoding='utf-8'?>
<document id="25052955"><sentence text="Selective induction of hepatic cytochrome P450 2B activity by leelamine in vivo, as a potent novel inducer."><entity charOffset="62-71" id="DDI-PubMed.25052955.s1.e0" text="leelamine" /></sentence><sentence text="Cytochrome P450 (CYP) is an important enzyme that can act on xenobiotic substances such as toxic chemicals or drugs" /><sentence text=" Phenobarbital (PB) has been widely used to induce CYP2B activity to investigate the drug-drug interaction of CYP2B substrate drugs"><entity charOffset="16-18" id="DDI-PubMed.25052955.s3.e0" text="PB" /></sentence><sentence text=" Leelamine is a diterpene compound, and is the current focus of efforts to develop a treatment for diabetes"><entity charOffset="1-10" id="DDI-PubMed.25052955.s4.e0" text="Leelamine" /><entity charOffset="16-25" id="DDI-PubMed.25052955.s4.e1" text="diterpene" /><pair ddi="false" e1="DDI-PubMed.25052955.s4.e0" e2="DDI-PubMed.25052955.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25052955.s4.e0" e2="DDI-PubMed.25052955.s4.e1" /></sentence><sentence text=" In this study, we identified the selective and potent inductive effect of leelamine on CYP2B at doses of 5, 10, or 20 mg/kg in male ICR mice for 1 or 3 days"><entity charOffset="75-84" id="DDI-PubMed.25052955.s5.e0" text="leelamine" /></sentence><sentence text=" In liver, the activity of CYP2B significantly increased 3" /><sentence text="6-fold after treatment with leelamine, compared to vehicle-treated group"><entity charOffset="28-37" id="DDI-PubMed.25052955.s7.e0" text="leelamine" /></sentence><sentence text=" Activities of benzyloxyresorufin O-dealkylase and pentoxyresorufin O-dealkylase significantly increased 6"><entity charOffset="15-33" id="DDI-PubMed.25052955.s8.e0" text="benzyloxyresorufin" /><entity charOffset="51-67" id="DDI-PubMed.25052955.s8.e1" text="pentoxyresorufin" /><pair ddi="false" e1="DDI-PubMed.25052955.s8.e0" e2="DDI-PubMed.25052955.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25052955.s8.e0" e2="DDI-PubMed.25052955.s8.e1" /></sentence><sentence text="3- and 5" /><sentence text="3-fold, respectively, with a single treatment of 20 mg/kg leelamine for 1 day"><entity charOffset="58-67" id="DDI-PubMed.25052955.s10.e0" text="leelamine" /></sentence><sentence text=" Furthermore, immunoblot analysis showed that significantly and dose-dependently increased CYP2B10 protein levels in liver" /><sentence text=" However, PCR results showed that there were no significant changes in the CAR and CYP2B mRNA levels after leelamine treatment"><entity charOffset="107-116" id="DDI-PubMed.25052955.s12.e0" text="leelamine" /></sentence><sentence text=" Accordingly, we suggest that leelamine is a novel substitute of PB for the selective induction of CYP2B activity in vivo"><entity charOffset="30-39" id="DDI-PubMed.25052955.s13.e0" text="leelamine" /><entity charOffset="65-73" id="DDI-PubMed.25052955.s13.e1" text="PB" /><pair ddi="false" e1="DDI-PubMed.25052955.s13.e0" e2="DDI-PubMed.25052955.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25052955.s13.e0" e2="DDI-PubMed.25052955.s13.e1" /></sentence><sentence text=" " /></document>